Thursday, October 22, 2026

Back to today

From X

@StableBread

Fajasy on X

Curtiss-Wright $CW is BWX Technologies’ $BWXT closest comp, and $BWXT trades below it on every measure but FCF yield. Since naval propulsion is close to half of $BWXT’s revenue, its closest comps are other Navy suppliers. Small-reactor developers like Oklo $OKLO and NuScale $SMR wouldn’t work anyway, as they lost $73.2M and $64.0M from operations in Q2 2026, leaving no EBITDA multiple to compare against. So I decided to compare $BWXT with four listed companies building or equipping the same Navy submarines and carriers: → Curtiss-Wright $CW: Pumps, valves, and turbines for the same submarines and carriers, plus reactor coolant pumps for Westinghouse’s AP1000. → Leonardo DRS $DRS: Naval power and propulsion systems, including electric drive equipment for the Columbia-class. → General Dynamics $GD: Builds the submarines through its Electric Boat unit. → Huntington Ingalls $HII: Builds the carriers and submarines at its Newport News shipyard. Here’s how they compare on 2026 estimates (P/E, EV/EBITDA, EV/sales, FCF yield): → $BWXT: 30.7x, 22.5x, 3.95x, 2.64% → $CW: 36.3x, 24.8x, 5.54x, 2.90% → $DRS: 26.9x, 18.4x, 2.48x, 2.78% → $GD: 19.7x, 13.9x, 1.68x, 5.34% → $HII: n/a, 12.3x, 0.98x, 5.28% Note: CW’s, GD’s, and HII’s EBITDA is operating income plus D&A from company guidance, since they don’t guide EBITDA. $BWXT trades above the two shipbuilders, which earn thinner margins. HII guides shipbuilding operating margins of 6.0-6.5% and GD 10.5% overall, vs. $BWXT’s 12.6% GAAP operating margin in 2025. A reasonable EV/EBITDA range for $BWXT is 16-24x, between its own end-2023 multiple and Curtiss-Wright’s today.

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY · long

Unicycive Therapeutics INC

Unicycive Therapeutics fell nearly 50% after a second FDA Complete Response Letter tied to a third-party manufacturer for its primary…

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

90 accounts

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.